ES2299841T3 - Composiciones farmaceuticas que comprenden azd2171 y zd6126, y usos de los mismos. - Google Patents

Composiciones farmaceuticas que comprenden azd2171 y zd6126, y usos de los mismos. Download PDF

Info

Publication number: ES2299841T3
Authority: ES; Spain
Prior art keywords: azd2171; combination; salt; pharmaceutically acceptable; treatment
Prior art date: 2003-07-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

ES04743280T

Other languages

English (en)

Spanish (es)

Inventor

Stephen Robert AstraZeneca R & D Alderley WEDGE

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

AstraZeneca AB

Original Assignee

AstraZeneca AB

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-07-10

Filing date

2004-07-07

Publication date

2008-06-01

2004-07-07 Application filed by AstraZeneca AB filed Critical AstraZeneca AB

2008-06-01 Application granted granted Critical

2008-06-01 Publication of ES2299841T3 publication Critical patent/ES2299841T3/es

2024-07-07 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 title claims abstract description 84
229960002412 cediranib Drugs 0.000 title claims abstract description 83
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 6
206010028980 Neoplasm Diseases 0.000 claims abstract description 41
241001465754 Metazoa Species 0.000 claims abstract description 29
238000004519 manufacturing process Methods 0.000 claims abstract description 25
239000003814 drug Substances 0.000 claims abstract description 17
201000011510 cancer Diseases 0.000 claims abstract description 13
150000003839 salts Chemical class 0.000 claims description 49
230000005865 ionizing radiation Effects 0.000 claims description 22
230000000259 anti-tumor effect Effects 0.000 claims description 10
230000001093 anti-cancer Effects 0.000 claims description 6
210000000481 breast Anatomy 0.000 claims description 5
210000001072 colon Anatomy 0.000 claims description 5
239000008280 blood Substances 0.000 claims description 4
210000004369 blood Anatomy 0.000 claims description 4
210000003734 kidney Anatomy 0.000 claims description 4
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
210000000664 rectum Anatomy 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 2
208000020816 lung neoplasm Diseases 0.000 claims 2
206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
201000005202 lung cancer Diseases 0.000 claims 1
208000037841 lung tumor Diseases 0.000 claims 1
238000011282 treatment Methods 0.000 abstract description 31
238000000034 method Methods 0.000 abstract description 9
238000002560 therapeutic procedure Methods 0.000 abstract description 9
230000008728 vascular permeability Effects 0.000 abstract description 9
230000005855 radiation Effects 0.000 abstract description 8
230000001772 anti-angiogenic effect Effects 0.000 abstract description 6
239000013066 combination product Substances 0.000 abstract description 3
229940127555 combination product Drugs 0.000 abstract description 3
230000001603 reducing effect Effects 0.000 abstract description 3
230000000694 effects Effects 0.000 description 30
238000011284 combination treatment Methods 0.000 description 25
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 13
102100039037 Vascular endothelial growth factor A Human genes 0.000 description 13
150000001875 compounds Chemical class 0.000 description 11
230000004044 response Effects 0.000 description 10
238000001959 radiotherapy Methods 0.000 description 9
230000004614 tumor growth Effects 0.000 description 8
210000005166 vasculature Anatomy 0.000 description 8
201000010099 disease Diseases 0.000 description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
230000012010 growth Effects 0.000 description 7
108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 6
230000033115 angiogenesis Effects 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
-1 cyclohepten-3-yl Chemical group 0.000 description 6
230000006378 damage Effects 0.000 description 6
230000002969 morbid Effects 0.000 description 6
239000000243 solution Substances 0.000 description 6
230000004083 survival effect Effects 0.000 description 6
102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 5
239000002253 acid Substances 0.000 description 5
210000004027 cell Anatomy 0.000 description 5
239000003112 inhibitor Substances 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
239000000203 mixture Substances 0.000 description 5
108091008598 receptor tyrosine kinases Proteins 0.000 description 5
102000027426 receptor tyrosine kinases Human genes 0.000 description 5
102000005962 receptors Human genes 0.000 description 5
108020003175 receptors Proteins 0.000 description 5
230000000306 recurrent effect Effects 0.000 description 5
230000002195 synergetic effect Effects 0.000 description 5
101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 4
206010061818 Disease progression Diseases 0.000 description 4
208000007766 Kaposi sarcoma Diseases 0.000 description 4
101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 4
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 4
230000009286 beneficial effect Effects 0.000 description 4
230000005750 disease progression Effects 0.000 description 4
150000007529 inorganic bases Chemical class 0.000 description 4
210000004072 lung Anatomy 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
206010003210 Arteriosclerosis Diseases 0.000 description 3
208000037260 Atherosclerotic Plaque Diseases 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
206010029113 Neovascularisation Diseases 0.000 description 3
208000034038 Pathologic Neovascularization Diseases 0.000 description 3
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
201000004681 Psoriasis Diseases 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
230000001154 acute effect Effects 0.000 description 3
239000002246 antineoplastic agent Substances 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000002775 capsule Substances 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
210000002889 endothelial cell Anatomy 0.000 description 3
201000011066 hemangioma Diseases 0.000 description 3
150000007530 organic bases Chemical class 0.000 description 3
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
230000026731 phosphorylation Effects 0.000 description 3
238000006366 phosphorylation reaction Methods 0.000 description 3
230000008569 process Effects 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
206010039073 rheumatoid arthritis Diseases 0.000 description 3
239000007787 solid Substances 0.000 description 3
238000001356 surgical procedure Methods 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
239000004066 vascular targeting agent Substances 0.000 description 3
206010051113 Arterial restenosis Diseases 0.000 description 2
206010009944 Colon cancer Diseases 0.000 description 2
208000001333 Colorectal Neoplasms Diseases 0.000 description 2
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
201000009273 Endometriosis Diseases 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
102000014150 Interferons Human genes 0.000 description 2
108010050904 Interferons Proteins 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
206010025282 Lymphoedema Diseases 0.000 description 2
206010025323 Lymphomas Diseases 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
206010027514 Metrorrhagia Diseases 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
208000034578 Multiple myelomas Diseases 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
206010035226 Plasma cell myeloma Diseases 0.000 description 2
102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 2
108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
229910052783 alkali metal Inorganic materials 0.000 description 2
238000013459 approach Methods 0.000 description 2
230000037396 body weight Effects 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
239000003638 chemical reducing agent Substances 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
201000010989 colorectal carcinoma Diseases 0.000 description 2
238000002648 combination therapy Methods 0.000 description 2
229940127089 cytotoxic agent Drugs 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
229960001776 edrecolomab Drugs 0.000 description 2
210000003989 endothelium vascular Anatomy 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
239000000367 immunologic factor Substances 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
229940079322 interferon Drugs 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
208000017169 kidney disease Diseases 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
208000002502 lymphedema Diseases 0.000 description 2
208000002780 macular degeneration Diseases 0.000 description 2
230000005012 migration Effects 0.000 description 2
238000013508 migration Methods 0.000 description 2
208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
238000011321 prophylaxis Methods 0.000 description 2
210000002307 prostate Anatomy 0.000 description 2
210000001210 retinal vessel Anatomy 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011734 sodium Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
230000002792 vascular Effects 0.000 description 2
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
FRIBMENBGGCKPD-UHFFFAOYSA-N 3-(2,3-dimethoxyphenyl)prop-2-enal Chemical compound COC1=CC=CC(C=CC=O)=C1OC FRIBMENBGGCKPD-UHFFFAOYSA-N 0.000 description 1
102000015790 Asparaginase Human genes 0.000 description 1
108010024976 Asparaginase Proteins 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
108010006654 Bleomycin Proteins 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
208000032544 Cicatrix Diseases 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
206010012689 Diabetic retinopathy Diseases 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
101150009958 FLT4 gene Proteins 0.000 description 1
108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
206010053759 Growth retardation Diseases 0.000 description 1
101600082430 Homo sapiens Vascular endothelial growth factor A (isoform VEGF165) Proteins 0.000 description 1
VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
208000022873 Ocular disease Diseases 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
239000004365 Protease Substances 0.000 description 1
229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
101710183280 Topoisomerase Proteins 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
206010054094 Tumour necrosis Diseases 0.000 description 1
108091008605 VEGF receptors Proteins 0.000 description 1
102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 1
102000016663 Vascular Endothelial Growth Factor Receptor-3 Human genes 0.000 description 1
108010034265 Vascular Endothelial Growth Factor Receptors Proteins 0.000 description 1
102300041083 Vascular endothelial growth factor A isoform VEGF165 Human genes 0.000 description 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
SWPYNTWPIAZGLT-UHFFFAOYSA-N [amino(ethoxy)phosphanyl]oxyethane Chemical compound CCOP(N)OCC SWPYNTWPIAZGLT-UHFFFAOYSA-N 0.000 description 1
125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
208000038016 acute inflammation Diseases 0.000 description 1
230000006022 acute inflammation Effects 0.000 description 1
229940009456 adriamycin Drugs 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
230000004075 alteration Effects 0.000 description 1
150000001413 amino acids Chemical group 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
239000004037 angiogenesis inhibitor Substances 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
230000003388 anti-hormonal effect Effects 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
229960003272 asparaginase Drugs 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
238000003556 assay Methods 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
229960001561 bleomycin Drugs 0.000 description 1
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
230000003185 calcium uptake Effects 0.000 description 1
229960004562 carboplatin Drugs 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
DGLFSNZWRYADFC-UHFFFAOYSA-N chembl2334586 Chemical compound C1CCC2=CN=C(N)N=C2C2=C1NC1=CC=C(C#CC(C)(O)C)C=C12 DGLFSNZWRYADFC-UHFFFAOYSA-N 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
230000008602 contraction Effects 0.000 description 1
239000006071 cream Substances 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
229960003668 docetaxel Drugs 0.000 description 1
230000013020 embryo development Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
229960005420 etoposide Drugs 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
208000030533 eye disease Diseases 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
229960002949 fluorouracil Drugs 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
231100000001 growth retardation Toxicity 0.000 description 1
FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
229960001330 hydroxycarbamide Drugs 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000000138 intercalating agent Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229960004768 irinotecan Drugs 0.000 description 1
UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
239000003446 ligand Substances 0.000 description 1
108020001756 ligand binding domains Proteins 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000002609 medium Substances 0.000 description 1
229910052751 metal Chemical class 0.000 description 1
239000002184 metal Chemical class 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
230000000394 mitotic effect Effects 0.000 description 1
239000002674 ointment Substances 0.000 description 1
230000008520 organization Effects 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000035699 permeability Effects 0.000 description 1
150000008301 phosphite esters Chemical class 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical class [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
150000003246 quinazolines Chemical class 0.000 description 1
229960004432 raltitrexed Drugs 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
231100000241 scar Toxicity 0.000 description 1
230000037387 scars Effects 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
241000894007 species Species 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000012353 t test Methods 0.000 description 1
229960001603 tamoxifen Drugs 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
239000003734 thymidylate synthase inhibitor Substances 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
229960000303 topotecan Drugs 0.000 description 1
UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
230000006444 vascular growth Effects 0.000 description 1
230000004862 vasculogenesis Effects 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
210000003905 vulva Anatomy 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
230000029663 wound healing Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Iron Core Of Rotating Electric Machines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

ES04743280T 2003-07-10 2004-07-07 Composiciones farmaceuticas que comprenden azd2171 y zd6126, y usos de los mismos. Expired - Lifetime ES2299841T3 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB0316123		2003-07-10
GBGB0316123.9A GB0316123D0 (en)	2003-07-10	2003-07-10	Combination therapy

Publications (1)

Publication Number	Publication Date
ES2299841T3 true ES2299841T3 (es)	2008-06-01

Family

ID=27741905

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES04743280T Expired - Lifetime ES2299841T3 (es)	2003-07-10	2004-07-07	Composiciones farmaceuticas que comprenden azd2171 y zd6126, y usos de los mismos.

Country Status (18)

Country	Link
US (1)	US20060160775A1 (zh)
EP (1)	EP1651227B1 (zh)
JP (1)	JP2007526887A (zh)
KR (1)	KR20060034287A (zh)
CN (1)	CN100435799C (zh)
AT (1)	ATE385798T1 (zh)
AU (1)	AU2004255023B2 (zh)
BR (1)	BRPI0412450A (zh)
CA (1)	CA2531643A1 (zh)
DE (1)	DE602004011781T2 (zh)
ES (1)	ES2299841T3 (zh)
GB (1)	GB0316123D0 (zh)
HK (1)	HK1089384A1 (zh)
IL (1)	IL172682A0 (zh)
MX (1)	MXPA06000413A (zh)
NO (1)	NO20056171L (zh)
WO (1)	WO2005004871A1 (zh)
ZA (1)	ZA200600188B (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0008269D0 (en)	2000-04-05	2000-05-24	Astrazeneca Ab	Combination chemotherapy
GB0310401D0 (en) *	2003-05-07	2003-06-11	Astrazeneca Ab	Therapeutic agent
BRPI0508959A (pt) *	2004-03-23	2007-08-14	Astrazeneca Ab	uso de azd2171 ou de um sal do mesmo farmaceuticamente aceitável, uso de sal maleato de azd2171 e oxaliplatina, composição farmacêutica, kit, e, método para a produção de um efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente
GB0406445D0 (en) *	2004-03-23	2004-04-28	Astrazeneca Ab	Combination therapy
CA2614002A1 (en) *	2005-07-06	2007-01-11	Astrazeneca Ab	Combination therapy of cancer with azd2171 and gemcitabine
PT1965801E (pt) *	2005-12-22	2011-05-25	Astrazeneca Ab	Combina??o de azd2171 e pemetrexed
TW200922590A (en) *	2007-09-10	2009-06-01	Curis Inc	VEGFR inhibitors containing a zinc binding moiety

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9714249D0 (en) *	1997-07-08	1997-09-10	Angiogene Pharm Ltd	Vascular damaging agents
CA2335038A1 (en) *	1998-06-15	1999-12-23	Arch Development Corporation	Combination of radiotherapy and anti-angiogenic factors
ATE482946T1 (de) *	1999-02-10	2010-10-15	Astrazeneca Ab	Chinazolinderivate als angiogenesehemmer und zwischenprodukte dafür
PL357282A1 (en) *	2000-03-31	2004-07-26	Angiogene Pharmaceuticals Ltd.	Divided dose therapies with vascular damaging activity
EE200200565A (et) *	2000-03-31	2004-06-15	Angiogene Pharmaceuticals Ltd.	Vaskulaarse kahjustava toimega kombinatsioonravi
GB0008269D0 (en) *	2000-04-05	2000-05-24	Astrazeneca Ab	Combination chemotherapy

2003
- 2003-07-10 GB GBGB0316123.9A patent/GB0316123D0/en not_active Ceased
2004
- 2004-07-07 CA CA002531643A patent/CA2531643A1/en not_active Abandoned
- 2004-07-07 WO PCT/GB2004/002937 patent/WO2005004871A1/en active IP Right Grant
- 2004-07-07 KR KR1020067000639A patent/KR20060034287A/ko not_active Application Discontinuation
- 2004-07-07 MX MXPA06000413A patent/MXPA06000413A/es active IP Right Grant
- 2004-07-07 JP JP2006518354A patent/JP2007526887A/ja active Pending
- 2004-07-07 BR BRPI0412450-2A patent/BRPI0412450A/pt not_active IP Right Cessation
- 2004-07-07 ES ES04743280T patent/ES2299841T3/es not_active Expired - Lifetime
- 2004-07-07 DE DE602004011781T patent/DE602004011781T2/de not_active Expired - Fee Related
- 2004-07-07 AT AT04743280T patent/ATE385798T1/de not_active IP Right Cessation
- 2004-07-07 AU AU2004255023A patent/AU2004255023B2/en not_active Ceased
- 2004-07-07 EP EP04743280A patent/EP1651227B1/en not_active Expired - Lifetime
- 2004-07-07 US US10/563,440 patent/US20060160775A1/en not_active Abandoned
- 2004-07-07 CN CNB2004800194887A patent/CN100435799C/zh not_active Expired - Fee Related
2005
- 2005-12-19 IL IL172682A patent/IL172682A0/en unknown
- 2005-12-23 NO NO20056171A patent/NO20056171L/no not_active Application Discontinuation
2006
- 2006-01-09 ZA ZA200600188A patent/ZA200600188B/xx unknown
- 2006-09-08 HK HK06110018A patent/HK1089384A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
ZA200600188B (en)	2007-04-25
HK1089384A1 (en)	2006-12-01
CN100435799C (zh)	2008-11-26
EP1651227B1 (en)	2008-02-13
MXPA06000413A (es)	2006-03-17
GB0316123D0 (en)	2003-08-13
EP1651227A1 (en)	2006-05-03
US20060160775A1 (en)	2006-07-20
WO2005004871A1 (en)	2005-01-20
NO20056171L (no)	2006-02-07
CN1819830A (zh)	2006-08-16
DE602004011781D1 (de)	2008-03-27
DE602004011781T2 (de)	2009-02-19
BRPI0412450A (pt)	2006-09-19
AU2004255023B2 (en)	2007-09-27
ATE385798T1 (de)	2008-03-15
JP2007526887A (ja)	2007-09-20
IL172682A0 (en)	2006-04-10
AU2004255023A1 (en)	2005-01-20
CA2531643A1 (en)	2005-01-20
KR20060034287A (ko)	2006-04-21

Publication	Publication Date	Title
CA2531862C (en)	2011-10-25	Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
ES2399768T3 (es)	2013-04-03	Combinación de ZD6474 y bevacizumab para terapia del cáncer
KR20070072543A (ko)	2007-07-04	Ｚｄ6474 및 이마티닙을 포함하는 병합법
JP2008514576A (ja)	2008-05-08	Ａｚｄ２１７１およびイマチニブを含む癌組合せ療法
BRPI0620118A2 (pt)	2011-11-01	uso de azd2171 ou de um sal farmaceuticamente aceitável do mesmo e de permetrexed, composição farmacêutica, kit, e, método para a produção de um efeito de redução da permeabilidade antiangiogênica, e/ou vascular em um animal de sangue quente
AU2006264620B2 (en)	2009-10-22	Combination therapy of cancer with AZD2171 and gemcitabine
ES2299841T3 (es)	2008-06-01	Composiciones farmaceuticas que comprenden azd2171 y zd6126, y usos de los mismos.
ES2313033T3 (es)	2009-03-01	Terapia de combinacion de cancer que comprende azd2171 y zd1839.
ES2335292T3 (es)	2010-03-24	Terapia de combinacion con azd2171 y 5-fu y/o cpt-11.
ES2335291T3 (es)	2010-03-24	Terapia de combinacion con azd-2171.
JP2007530517A (ja)	2007-11-01	組合せ療法
ES2364030T3 (es)	2011-08-23	Terapia de combinación de zd6474 con 5-fu y/o cpt-11.
ES2349194T3 (es)	2010-12-28	Uso del derivado de quinazolina zd6474 combinado con compuestos de platino y opcionalmente radiación ionizante en el tratamiento de enfermedades asociadas con angiogénesis y/o permeabilidad vascular aumentada.
ES2360880T3 (es)	2011-06-09	Combinación de zd6474 y pemetrexed.
ES2361682T3 (es)	2011-06-21	Combinación de azd2171 y pemetrexed.
ZA200607550B (en)	2008-05-28	Combination therapy
WO2009118560A1 (en)	2009-10-01	Combination therapy 038